Triple-negative breast cancer trials in United States

In United States 174 Also abroad 425

174 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Not yet taking people in United States
Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer
Where
Columbus
Age
18 years and over
People
84
Run by
Ohio State University Comprehensive Cancer Center
See details and how to joinNCT07217990
No phaseTaking people
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Where
Bethesda
Age
18 years to 120 years
People
139
Run by
National Cancer Institute (NCI)
See details and how to joinNCT07619534
Phase 1Taking people
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
Where
Grand Rapids, Los Angeles, Nashville, San Antonio
Age
18 years and over
People
60
Run by
Immunomic Therapeutics, Inc.
See details and how to joinNCT07652242
Phase 1/2Taking people
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Where
Chattanooga, Columbus, Duarte, Durham, Germantown, Hackensack, Howell Township, Irvine, La Jolla, Longmont, Los Angeles, Nashville, New Brunswick, New York, Omaha, Philadelphia, Pittsburgh, Plano, Reno, Saint Paul, Stanford, Tampa, Zion
Age
18 years and over
People
1,132 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT03424005 · EU 2023-503629-20-00
Phase 2Taking people
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
Where
Aurora, Aventura, Baltimore, City of Saint Peters, Clemmons, Columbus, Coral Gables, Creve Coeur, Deerfield Beach, Galveston, Hartford, Lebanon, Miami, New Haven, New York, Oklahoma City, Orange, Pittsburgh, Plantation, Richmond, Sacramento, St Louis, Tampa, Wesley Chapel, Winston-Salem
Age
18 years and over
People
86
Run by
National Cancer Institute (NCI)
See details and how to joinNCT03606967
Phase 3Taking people
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Where
Abilene, Albuquerque, Alexandria, Altamonte Springs, Amarillo, Ann Arbor, Arlington Heights, Bismarck, Canton, Carterville, Chandler, Charlotte, Dallas, Detroit, Dyer, Edgewood, Fargo, Farmington, Fayetteville, Fenton, Flower Mound, Fort Wayne, Fort Worth, Fountain Valley, Fredericksburg, Germantown, Grand Forks, Grand Junction, Houston, Jackson, La Jolla, Laredo, Las Vegas, Los Alamitos, Madison, Massillon, Maumee, Memphis, Midlothian, Mobile, Monroe, Murray, Nashville, Newark, New Haven, New York, Norfolk, Oakland, Oceanside, Oklahoma City, Orlando, Osage Beach, Philadelphia, Portland, Richmond, Roseville, Royal Oak, Saint Louis Park, San Antonio, San Francisco, Santa Clara, Santa Fe, Santa Rosa, Shreveport, Silver Spring, Sioux Falls, Skokie, St Louis, St. Petersburg, Stuart, Tacoma, Thomasville, Tulsa, Tyler, Vallejo, Walnut Creek, Webster, Westbury, Wichita, York, Zanesville
Age
18 years and over
People
1,530 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06393374 · EU 2023-504962-52-00
Phase 1Taking people
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Where
Atlanta, Augusta, Austin, Boston, Charlottesville, Dallas, Denver, Fairfax, Fairway, Hackensack, Lake Mary, Little Rock, Los Angeles, Nashville, Orlando, Philadelphia, Pittsburgh, Salt Lake City, San Francisco
Age
19 years and over
People
238 worldwide
Run by
NiKang Therapeutics, Inc.
See details and how to joinNCT06586957
Phase 1Taking people
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Where
Boston, Cleveland, Dallas, Denver, Duarte, Fairfax, Grand Rapids, Houston, Iowa City, La Jolla, Las Vegas, Morgantown, New Haven, Pittsburgh, San Antonio, Sarasota, St Louis, Washington D.C., West Valley City
Age
18 years and over
People
361
Run by
NiKang Therapeutics, Inc.
See details and how to joinNCT07029399
Phase 1Not yet taking people in United States
Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients
Where
St Louis
Age
18 years and over
People
30
Run by
Washington University School of Medicine
See details and how to joinNCT07300475
Phase 1Taking people
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Where
Conroe, Duarte, Grand Rapids, Houston, League City, Long Island City, New York, San Antonio, Sugar Land, West Valley City
Age
18 years and over
People
260 worldwide
Run by
Pfizer
See details and how to joinNCT07318805 · EU 2025-524387-38-00
Phase 1/2Taking people
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Where
Abilene, Augusta, Austin, Boston, Camden, Columbus, Dallas, Detroit, Doylestown, Eugene, Everett, Fairfax, Fort Myers, Fort Worth, Grand Rapids, Los Angeles, Maplewood, Nashville, Norfolk, Oklahoma City, Phoenix, Pittsburgh, Portland, Providence, Rockville, San Diego, Santa Barbara, Santa Rosa, St. Petersburg, Tucson, Tyler, West Palm Beach, West Valley City, Westwood, Woodland
Age
18 years and over
People
952 worldwide
Run by
Genmab
See details and how to joinNCT05579366
Phase 3Taking people
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Where
Abilene, Albuquerque, Amsterdam, Appleton, Athens, Atlanta, Aurora, Austin, Baltimore, Baton Rouge, Bend, Berkeley, Bethesda, Bethlehem, Birmingham, Boise, Boston, Buffalo, Cedar Rapids, Chapel Hill, Charleston, Charlotte, Charlottesville, Chicago, Cincinnati, Clearwater, Clovis, Coeur d'Alene, Columbus, Corvallis, Danbury, Des Moines, Detroit, Downey, Durham, East Brunswick, East Syracuse, El Paso, Eugene, Evanston, Fairfax, Farmington, Flemington, Florham Park, Fountain Valley, Foxborough, Franklin, Frederick, Gainesville, Glendale, Grand Rapids, Green Bay, Greensboro, Greenville, Grosse Pointe Woods, Hastings, Houston, Huntsville, Indianapolis, Iowa City, Jacksonville, Jupiter, Kingsport, Knoxville, Lacey, Lafayette, Lake Success, Lancaster, Las Vegas, Lexington, Los Angeles, Louisville, Lubbock, Madison, Maplewood, Marietta, Medford, Methuen, Miami Beach, Midlothian, Milford, Minneapolis, Morgantown, Munster, Naperville, New Brunswick, Newnan, New Orleans, Newport Beach, New York, Oklahoma City, Omaha, Orange City, Orlando, Paducah, Palm Bay, Pembroke Pines, Pensacola, Philadelphia, Phoenix, Pinehurst, Pittsburgh, Plantation, Portland, Prescott Valley, Providence, Puyallup, Raleigh, Rapid City, Redlands, Reno, Renton, Richmond, River Forest, Rochester, Rocky Mount, Royal Oak, Sacramento, Saint Louis Park, Salt Lake City, San Antonio, San Francisco, Santa Barbara, Sayre, Scarborough, Shirley, Sioux Falls, Skokie, Southfield, South Weymouth, Spartanburg, Spokane, Springfield, Stamford, St Louis, Stockton, Stony Brook, Stuart, Summit, Syracuse, Tampa, The Bronx, Toledo, Towson, Urbana, Valdosta, Washington D.C., Westbury, Weston, West Reading, White Plains, Wichita, Winston-Salem, Worcester, Wynnewood, Wytheville, York, Ypsilanti
Age
18 years and over
People
1,514 worldwide
Run by
Gilead Sciences
See details and how to joinNCT05633654 · EU 2024-512279-10-00
Phase 1Taking people
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Where
Athens, Birmingham, Boston, Buffalo, Fort Wayne, Margate, Nashville, Orlando, Palo Alto, Sarasota, Spokane
Age
18 years and over
People
85
Run by
Compass Therapeutics
See details and how to joinNCT06150664
Phase 1Taking people
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Where
Atlanta, Columbus, Falls Church, Grand Rapids, Houston, La Jolla, Mineola, New York, Scottsdale, West Valley City
Age
18 years and over
People
575 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00
Phase 1Taking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Atlanta, Boston, Chicago, Cleveland, Denver, Duarte, Grand Rapids, Houston, Indianapolis, La Jolla, Los Angeles, Nashville, New York, Salt Lake City, San Antonio, St Louis, St. Petersburg, West Valley City
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Phase 2Not yet taking people in United States
US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and Chemotherapy
Where
Atlanta
Age
18 years and over
People
32
Run by
Emory University
See details and how to joinNCT07862751
Phase 2Taking people
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
Where
Houston
Age
18 years and over
People
120
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT07407920
Phase 2Not yet taking people in United States
Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer
Where
Kansas City, St Louis
Age
18 years and over
People
17
Run by
Washington University School of Medicine
See details and how to joinNCT07914309
Phase 1Taking people
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Where
Boston, Cincinnati
Age
18 years and over
People
90
Run by
Andrew Hantel, MD
See details and how to joinNCT07341867
Phase 1/2Taking people
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer and HR+/HER2- Metastatic Breast Cancer
Where
Los Angeles
Age
18 years and over
People
34
Run by
Yuan Yuan
See details and how to joinNCT05318469
Phase 2Taking people
Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
Where
Salt Lake City
Age
18 years and over
People
80
Run by
University of Utah
See details and how to joinNCT05464082
Phase 1Taking people
Study of XB010 in Subjects With Solid Tumors
Where
Atlanta, Austin, Chicago, Dallas, Fairfax, Houston, Huntersville, Irvine, Los Angeles, Nashville, Oklahoma City, Orlando, St Louis, The Bronx, Washington D.C.
Age
18 years and over
People
396 worldwide
Run by
Exelixis
See details and how to joinNCT06545331
Phase 3Taking people
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Where
Arlington, Baltimore, Bay Shore, Bend, Burleson, Burlington, Charlotte, Columbia, Dallas, Decatur, Detroit, Florham Park, Fort Myers, Fort Worth, Germantown, Grand Island, Houston, Kansas City, La Jolla, Livingston, Long Branch, Los Alamitos, Los Angeles, Louisville, Mechanicsville, Midlothian, Milwaukee, Nashville, Newark, New Brunswick, New York, O'Fallon, Omaha, Palm Bay, Palo Alto, Pensacola, Portland, Redmond, Richardson, Richmond, Rochester, Royal Oak, Sacramento, Saint Louis Park, Saint Paul, Salem, Santa Barbara, Santa Monica, Somerville, Springdale, Stony Brook, St. Petersburg, Tacoma, The Bronx, The Woodlands, Toms River, Urbana, Weatherford, Westbrook
Age
18 years and over
People
558 worldwide
Run by
BioNTech SE
See details and how to joinNCT07173751 · EU 2025-521884-12-00
Phase 1Taking people
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Where
Aurora, Boston, Chicago, Duarte, La Jolla, Nashville, New York
Age
18 years and over
People
52
Run by
Mabwell (Shanghai) Bioscience Co., Ltd.
See details and how to joinNCT06908928
No phaseTaking people
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Where
Boston, Columbus, Duarte, Gilbert, Houston, Jacksonville, La Jolla, Nashville, New York, Palo Alto, Phoenix, Rochester, Santa Monica, Seattle, St Louis, Tampa
Age
18 years and over
People
500
Run by
A2 Biotherapeutics Inc.
See details and how to joinNCT04981119